LLY
LLY's valuation is historically cheap, fundamentals are above averages and forward estimates point to improving growth and profitability.
LLY vs Historical averages
| Metric | Current | AverageAverage | Relative |
|---|---|---|---|
| PE | 37x | 57x | 35% lower-35% |
| PE percentile | 30 | 50 | 40% lower-40% |
| EPS | $29.80 | $9.50 | 214% higher+214% |
| FCF | $20.1B | $3.2B | 525% higher+525% |
| Loading historical comparisons… | |||
LLY’s earnings and cash flow are above their historical averages, while its earnings multiple is lower.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Forward valuation | Strongly improving |
| Forward earnings | Strong growth |
| Forward revenue | Growth |
| Forward profitability | Expanding |
| Analyst coverage | Moderate |
| Estimate dispersion | Moderate |
LLY’s outlook is generally improving, with growth expectations supporting the valuation case.
LLY PE Valuation
This table applies LLY's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.
LLY Earnings Per Share
This chart tracks LLY's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.
LLY Quarterly Revenue
This chart tracks LLY's quarterly revenue over time and shows how sales are changing from year to year.
LLY Free Cash Flow
This chart tracks LLY's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.
LLY Total Shares
This chart tracks changes in LLY's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.
LLY Net Leverage
Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.
LLY PE vs Healthcare Sector
This chart compares LLY's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.
LLY Weekly Price
This chart uses LLY's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.
LLY Weekly Moving Averages
This chart compares LLY's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.
LLY Yearly ROI
Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.
NVAX
NVAX's valuation appears fair, weak fundamentals weigh on the score and a weakening outlook adds pressure, though analyst coverage is limited and estimates vary widely.
NVAX vs Historical averages
| Metric | Current | AverageAverage | Relative |
|---|---|---|---|
| PE | 2.9x | 3.1x | 5% lower-5% |
| PE percentile | 29 | 50 | 42% lower-42% |
| EPS | -$1.52 | -$7.15 | $5.63 higher+$5.63 |
| FCF | -$43.6M | -$273.5M | +$229.9M+$229.9M |
| Loading historical comparisons… | |||
NVAX’s earnings are above their historical averages, while its earnings multiple is lower.
NVAX Forward outlook
| Metric | Outlook |
|---|---|
| Forward valuation | -- |
| Forward earnings | Loss stable |
| Forward revenue | Strong decline |
| Forward profitability | Strongly contracting |
| Analyst coverage | Limited |
| Estimate dispersion | Wide |
NVAX’s outlook is weakening, with declining sales expectations a concern.
NVAX PE Valuation
This table applies NVAX's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.
NVAX Earnings Per Share
This chart tracks NVAX's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.
NVAX Quarterly Revenue
This chart tracks NVAX's quarterly revenue over time and shows how sales are changing from year to year.
NVAX Free Cash Flow
This chart tracks NVAX's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.
NVAX Total Shares
This chart tracks changes in NVAX's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.
NVAX Net Leverage
Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.
NVAX PE vs Healthcare Sector
This chart compares NVAX's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.
NVAX Weekly Price
This chart uses NVAX's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.
NVAX Weekly Moving Averages
This chart compares NVAX's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.
NVAX Yearly ROI
Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.